Novel bitter melon extracts highly yielded from supercritical extraction reduce the adiposity through the enhanced lipid metabolism in mice fed a high fat diet  by Xu, Li et al.
lable at ScienceDirect
Journal of Nutrition & Intermediary Metabolism 6 (2016) 26e32Contents lists avaiJournal of Nutrition & Intermediary Metabolism
journal homepage: http : / /www.jnimonl ine.com/Novel bitter melon extracts highly yielded from supercritical
extraction reduce the adiposity through the enhanced lipid
metabolism in mice fed a high fat diet
Li Xu a, Yi Xu a, Shuang Wang a, Qianchun Deng b, Chun-Yan Wu a, Xiang-Tao Chen c,
Hui-Li Wang a, *
a School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, Anhui 230009, PR China
b Oil Crops Research Institute, Chinese Academy of Agricultural Sciences, Wuhan, PR China
c School of Pharmacy, Anhui Medical University, Hefei, Anhui 230031, PR Chinaa r t i c l e i n f o
Article history:
Received 18 September 2015
Received in revised form
5 January 2016
Accepted 15 April 2016





Supercritical extraction* Corresponding author.
E-mail address: wanghl@hfut.edu.cn (H.-L. Wang)
http://dx.doi.org/10.1016/j.jnim.2016.04.002
2352-3859/© 2016 The Authors. Published by Elseviera b s t r a c t
Bitter melon (Momordica charantia) is a species of edible plant known for its medicinal value towards
diabetes and obesity. Due to the various compositions of bitter melon extracts (BME), the comprehensive
knowledge concerning their anti-obesity effects was insufﬁcient. Here we ﬁrst introduced supercritical
extraction to BME's preparation, (supercritical extraction is a relatively advanced extraction method with
a better efﬁciency and selectivity and expected to be extensively used in future applications) and the
resultants were subjected to HPLC analysis, validating the presence of 42.60% of conjugated linolenic acid
(CLnA, cis9, trans11, trans13-18:3) and 13.17% of conjugated linoleic acid (CLA, cis9, trans11-18:2). The
BMSO (bitter melon seed oil) was then administered to the HFD mice, an obesity model established by
feeding C57BL/6J mice a high fat diet. Consequently, due to the BMSO's supplementation, the HFD mice
showed a signiﬁcantly decreased body-weight, Lee's index, fat index and adipose size, whereas the liver
weight stayed unchanged. Meanwhile, the serum FFA (free fatty acids) levels returned to normal at the
dosage of 10 g/kg, and the elevated serum leptin levels were also recovered by BMSO's supplementation
with moderate and high dose. These ﬁndings suggested that BMSO restored the balance between lipid
intake and metabolism, which was probably mediated by leptin's variation. In summary, a detailed anti-
obesity effect was described with regard to a potent CFA's (conjugated fatty acid) combination offered by
BME. A potential mechanism underlying BME's beneﬁcial effects was proposed, paving the way for the
better use of BME's pharmaceutical function to serve the obesity's treatment.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Obesity, a complex metabolic disorder, has become one of the
main health and public issues in both developed and developing
countries [1,2]. In the US, over one-third adults and 16.7% children
were obese in 2009e2010, which costs up to 200 billion US dollars
annually [3]. What's more, in economically advanced countries,
socioeconomic inequalities in overweight and obesity continue to
widen [4]. Meanwhile, there were about 200 million people who
were affected by obesity in 2007 in China [5]. Given its associations
with many life-threatening chronic diseases, such as insulin.
Inc. This is an open access article uresistance, type II diabetes, reproductive system diseases and even
cancers [6, 7], it's urgent to ﬁnd safe and effective therapies for
obesity and its complications. Especially, the search for the cost
effective and safe preparations to address the obesity issue needs to
be highlighted more.
As a species of medicinal and edible plant, themedicinal value of
bitter melon (Momordica charantia, Linn, Cucurbitaceae) [8] has
gradually drawn great attention. It has been evaluated as anti-
diabetic agent in several clinical tests [9], a potent agent prohibit-
ing the proliferation of sleeping sickness [10], an agent impairing
the prostate cancer progression [11] and its anti-obesity effect was
also studied and accepted [12e14]. Nonetheless, the reports per-
taining to the concrete fat-reducing effects were usually contra-
dictive, partially due to the inconsistent compositions of BME,
which was obtained using various extraction methods. Thesender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hexane extraction [16], as well as acetoacetic acid extraction [17].
Compared with the conventional methods used to obtain BMSO,
supercritical CO2 extraction has a range of advantages: the super-
critical ﬂuid has a higher diffusion coefﬁcient and lower viscosity;
repeated reﬂux provides complete extraction; the selectivity of
supercritical ﬂuid is higher, etc [18]. It's reasonable to deduce that
the supercritical extraction could lead to a BMSOwith higher yields
and varied constituents.
The etiology of obesity was generally associated with abnormal
changes of several tissues, such as adipocyte, serum and liver [19],
and the impaired energy homeostasis played essential roles in
obesity's development. As for the energy balance between intake
and expenditure, leptin's regulatory roles received the increasing
attention [20]. Leptin is the primary signal from energy storage and
functions negatively on energy intake [21], and Chen et al. [22]
showed that the increased leptin signaling could facilitate the
transformation of white adipocytes into fat-burning cells. In obese
model, the activity of leptin was inhibited, mainly via the “leptin
resistance”, a mechanism characterized by the reducedFig. 1. HPLC analysis of polyunsaturated fatty acids. A, standard sample of CLnA (cis9, trans1
seed oil) sample. The arrows indicated the objective characteristic peaks. Each experimenthypothalamic susceptibility towards leptin's presence. Additionally,
the leptin resistance was frequently accompanied by the increased
circulating leptin level [21]. Thus, leptin could bridge central ner-
vous system and peripheral tissues in energy regulation, and
whether its function was improved upon a novel BMSO's admin-
istration, needs a concise investigation.
The purpose of this paper is to perform a comprehensive study
on the anti-obesity effect of a novel BMSO and in further steps,
investigate the underlying regulatory mechanisms involved in this
advantageous effect. Besides, the function of conjugated fatty acids
(CFA) was also summarized and discussed.
2. Materials and methods
2.1. BMSO's preparation
Bitter melon seeds (purchased from Chengxin Herb Corporation,
Hebei province, China) collected from ripe bitter melons only, with
similar size, color, and no physical damage. BMSO's preparationwas
carried out as suggested previously [22] with some modiﬁcations:1, trans13-18:3); B, standard sample of CLA (cis9, trans11-18:2); C. BMSO(bitter melon
was repeated thrice, and results of a representative experiment are shown.
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a dehydrator for 3 h, got the shell off and ground using a sample
grinder. Then the seeds were ﬁltered to obtain a uniform particle
size. BMSO was extracted by supercritical CO2. The extraction were
carried out under the pressure of 25 MPa, with the temperature of
50 C for 100min. The extracted BMSO was stored separately
in 20 C. As the extracted BMSO's density was determined as
0.9 g/cm3, the volume of BMSO was converted into the mass by
multiplying 0.9 g/cm3.
2.2. Fatty acid analysis
The BMSO used in this study was dissolved in 0.5 mol/L KOH/
C2H5OH and reﬂuxed extraction for 30 min. After neutralized with
0.5 mol/L HCl, the solution was used for fatty acid analysis by HPLC.
The column was Kromasil 100-5 (AzkoNobel, Amsterdam,
Netherlands) C18 (4.6 mm*250mm*5 mm), acetonitrile dissolved in
0.1% phosphate saline solution was used as the mobile phase and
the ﬂowing rate was set as 1 ml/min. The column temperature was
kept as 30 C, and the detection wavelength was 203 nm. The
sample size is used as 10 ml. The retention time of various fatty acids
was detected and depicted.
Except for CLA and CLnA, the fatty acids proﬁling was as follows:
palmitic acid (1.557%), stearic acid (29. 589%), oleic acid (9.54%), and
other unidentiﬁed FAs.
2.3. Animals and diets
The four-week-old C57BL/6J male mice were obtained from the
Laboratory Animal Center, Anhui Medical University, P.R. China. All
the mice were SPF-grade and cultivated in SPF lab. Mice were
randomly divided into two groups: one group raised with High-Fat
Diet (HFD; lard oil 10%, egg yolk power 10%, butter 10%, peanut
butter 10%; n ¼ 50) and the other with chow diet (control; n ¼ 7).
Food intake and body weight was measured weekly. The average
weight of HFD group 20% higher over that of control group was
regarded as the criteria of successful obesity model.
Themicewere raised following the Guide for the Care and Use of
Laboratory Animals, published by the National Institutes of Health
(NIH Publication, 8th edition, 2011) and the ARRIVE guidelines
(Animal Research: Reporting In Vivo Experiments). TheFig. 2. The murine weight saltered with BMSO (bitter melon seed oil) supplementation. (A)T
of body lee's index. Data are expressed as mean ± SEM (n ¼ 6 for control, n ¼ 8 for HFD, n ¼
(10 g/kg)). P < 0.05 was considered as statistical difference (*p < 0.05, **p < 0.01, ***p < 0.experiments were approved by the Hefei University of Technology
Animal Care and Use Committee (No. 20140009).
HFD group were divided into four sub-groups randomly when
obesity model built, which were HFDgroup (n ¼ 8), HFD þ BMSO
(1 g/kg; n¼ 9), HFDþ BMSO (5 g/kg; n¼ 9), and HFDþ BMSO (10 g/
kg; n ¼ 9). BMSO treatment was applied by intragastric adminis-
tration while control and HFD groups were treated with water at
the same volume. The mice were subjected to the further test
following three-week's treatment.
2.4. Obesity index determination
Mice were sacriﬁced by anesthesia. Body weight and length
were measured before fat pad of perirenal and epididymal
collected. Fat index was measured with the ratio of total fat pad
weight (perirenal and epididymal fats) to body weight. Body length




body weight 103body lengthðcmÞs
q
2.5. Assessment of blood chemistry
After three-week BMSO treatment, micewere fasted for 16h and
sacriﬁced. The whole-blood sample was collected via cardiac
puncture, serum were collected with spun (3500 rpm) at 4 C for
10min. Serum leptin and FFA level were determined with mouse
Leptin ELISA Kits (R&D, American) and FFA ELISA Kits (R&D,
American), respectively. Serum TC and LDL-C levels were deter-
mined with L-Type CHO M (Hitachi, Japan) and HDL and LDL/VLDL
Quantiﬁcation Kit (Biovision, USA), respectively.
2.6. Adipose tissue and liver histology
Adipose tissue and liver histology was performed according to
the previous protocol [23]. Multiple sections were obtained from
epididymal adipose tissue, which was ﬁxed in 4% paraformaldehyde
overnight, and then promptly embedded with parafﬁn. The tissue
was sliced at scale of 4 mm, stained with hematoxylin and eosin (HE).ime course of body weight measured over three weeks of BMSO treatment. (B) Change
9 for HFD þ BMSO (1 g/kg), n ¼ 9 for HFD þ BMSO (5 g/kg) and n ¼ 9 for HFD þ BMSO
001).
Fig. 3. BMSO changed the physical properties of epididymal fat per unit area. (A) Histology of fat was analyzed by hematoxylin and eosin. Cell maximum diameter (B) and adipose
cell number (C) changed per ﬁeld. P < 0.05 was considered as statistical difference (*p < 0.05, **p < 0.01, ***p < 0.001).
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quired using digital microscopy (Olympus IX81) and analyzed by
Image-Pro Plus6.0 software. HE staining was also utilized to deter-
mine the morphology of the murine livers, with the extent of stea-
tosis described by the occurrences of hollow bubbles.
2.7. Statistical analysis
Data are expressed as the mean ± SEM. Comparison between
groups were analyzed by one-way ANOVA and unpaired two-tailed
Student's t test. The General Linear Model of the SPSS package was
used for statistical analyses. P < 0.05 was considered statistically
signiﬁcant.
3. Results & discussion
3.1. Supercritical CO2 extraction of BMSO
The extraction was carried out at a pressure of 10 Mpa, with atemperature of 50 C. Conjugated linolenic acid (CLnA, cis9, trans11,
trans13-18:3) could be extracted in the highest amount (42.60% of
the total lipid contents), followed by conjugated linoleic acid (CLA,
cis9, trans11-18:2; 13.17%) (Fig.1). Additionally, the total yields of FA
reached up to 36.1g/100 g BM, which was higher than that
extracted by the conventional hexane method (24.6g/100gBM
seeds) [22,24], revealing that the supercritical CO2 extraction was
indeed signiﬁcantly efﬁcient in extracting FAs from bitter melon
seeds. Additionally, Chen et al. [24], reported that the content of
CLA and CLnA was 6.4% and 50%, respectively, and in contrast with
it, HPLC analysis showed that the obtained BMSO possessed a
signiﬁcantly increased level of CLA, thereby becoming it a novel
BMSO with potentially varied anti-obesity activities.
3.2. BMSO reduced body weights of HFD mice
The high-fat induced obesity (HFD) mice model (the average
body weight of model group was 20% higher than that of control)
was built to investigate the anti-obesity effect of BMSO in C57BL/6J
Fig. 4. The body characteristics altered with BMSO supplementation. (A) Convert of fat mass, compared with total body weight. (B) Change of food consumption during BMSO
treatment. And effect of BMSO on serum TC (C) and LDL-C (D) levels in high fat diet-induced mice. Data are expressed as mean ± SEM (n ¼ 6 for control, n ¼ 8 for HFD, n ¼ 9 for
HFD þ BMSO (1 g/kg), n ¼ 9 for HFD þ BMSO (5 g/kg) and n ¼ 9 for HFD þ BMSO (10 g/kg)). P < 0.05 was considered as statistical difference (*p < 0.05, **p < 0.01, ***p < 0.001).
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5 g/kg, 10 g/kg BMSO for HFD, respectively) was carried out to
examine the body characteristics.
The results showed that the weight of HFD þ BMSO (10 g/kg)
group was 26.32 ± 0.74 g, while HFD and control group was
28.89 ± 1.23 g, 25.27 ± 0.49 g, respectively. This indicates that high
dose of BMSO could reduce weight gain signiﬁcantly compared
with that of HFD group (p < 0.05) (Fig. 2A). The Lee's index, which
was used to describe the degree of obesity, was also reduced by
5.28% for HFD þ BMSO (10 g/kg) group (Fig. 2B). On the other side,
the addition of low (1 g/kg) and moderate dose (5 g/kg) did not
show a signiﬁcant rescue, revealing that the fat-reducing effect was
dose-dependent. No signiﬁcant changes were observed at low and
moderate doses. In summary, these ﬁndings indicated that BMSO
could impose beneﬁcial effects on the obesity syndrome.3.3. BMSO's effects on adipose and liver
A comprehensive investigation for an anti-obesity effect should
include the experimental studies on the following tissues ororgans: adipocyte, blood and liver [19]. First, morphological anal-
ysis of BMSO-treatedmice in epididymal fat padswas performed by
HE staining. As shown in Fig. 3, the size of adipocyte was dramat-
ically reduced in HFD þ BMSO groups (41.25 ± 11.25 mm,
41.67 ± 6.82 mm and 46.88 ± 4.49 mm for high, moderate and low
doses, respectively), compared with that of HFD mice
(71.25 ± 3.61 mm, p < 0.05) (Fig. 3A,B). And the cell number in a
single unit vision returned to a normal level against the sharp
decline for HFDmice (Fig. 3A,C). These results suggested that BMSO
primarily exerted its beneﬁcial effects on the adipose tissue.
As the primary component of BMSO, CLnA was previously
shown to promote the apoptosis of preadipocytes through ERK/
MAPK's activation [17], but its direct link with the reduction of
adipocyte tissue remains elusive. Consequently, the exact compo-
nent responsible for the anti-obesity effects has not been identiﬁed
[17]. According to the ﬁndings here, it could be proposed that CLA
might play central roles in BMSO's effects, due to the exceptionally
large proportion of CLA in this study. Furthermore, CLA's anti-
obesity effect was previously identiﬁed when added to the mu-
rine diet alone [25]. Based on that, it's tempting to speculate that
Fig. 5. Effect of BMSO on liver in high fat diet-induced mice. (A) Histology of liver was
analyzed by hematoxylin and eosin. The magniﬁcations of histology were 400 times.
(B) Liver weight was weighted. P < 0.05 was considered as statistical difference
(*p < 0.05, **p < 0.01, ***p < 0.001).
Fig. 6. Effect of BMSO on serum leptin levels (A), and FFA levels (B) in high fat diet-induc
difference (*p < 0.05, **p < 0.01, ***p < 0.001).
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BMSO presented in this study beneﬁted mainly from its high CFA
yield and CLA proportion.
This argument could also be validated in part through the
comparison with BMSO prepared using alternative approaches.
Senanayake et al. [13] reported that the hexane extracts did not
reduce the adipocyte weights with statistical signiﬁcance; Huang
et al. [26] showed that the BM powder's addition lowered the ad-
ipose cell number; contrary to that, a hexane extract did markedly
decrease the adipocyte sizes [16], but its treatment lasted for 5
weeks, instead of 3 weeks in this study. The inconsistent results
might also be ascribed to the combinational effect of various CFAs.
An independent combination could generate a comparatively
different anti-obesity effect, and this interaction should be
considered very complex, as CLnA was easily converted into CLA
in vivo, particularly in adipose tissues [14].
Obesity is generally considered to arise from the impaired en-
ergy homeostasis, thus it's necessary to examine whether BMSO
affected the process of food intake or energy expenditure. Food
consumptionwas ﬁrst measured, and no differences were observed
between HFD and HFDþ BMSOmice (Fig. 4B), although a markedly
decreased fat index was shown upon BMSO's supplementation
(Fig. 4A). Moreover, with respect to serum TC and LDL-C, no sig-
niﬁcant inﬂuence imposed by BMSO was observed, either (Fig. 4C,
D). The ﬁndings here demonstrated that BMSO-led weight varia-
tions were not primarily due to the ﬂexibility of food intake.
Since liver is the central organ responsible for lipid metabolism,
we next examined the liver changes during BMSO's administration.
As shown in Fig. 5B, the liver weights remained invariable
throughout the tested groups. The BMSO's effect on the murine
liver is usually inconsistent, when both increased and decreased
liver weights were previously reported [25,27]. Liver weight was
thought to be related to the accelerated lipid conversion, but it
could not be regarded as a reliable mark, as demonstrated by the
heterogeneity of its alteration. However, the possibility that the
BMSO obtained here acted in a distinct mode, also could not be
excluded. In addition, it was revealed from Fig. 5A, that high fat diet
could induce mild steatosis, while BMSO could improve this situ-
ation. This result is in agreement with the view that BM could offer
efﬁcient protection towards liver through the antioxidant and anti-
inﬂammatory action.ed mice. All values are given as means ± SEM. P < 0.05 was considered as statistical
L. Xu et al. / Journal of Nutrition & Intermediary Metabolism 6 (2016) 26e32323.4. BMSO's effects resulted from increased lipid metabolism
In order to further investigate BMSO's effect on the murine lipid
metabolism, the serum FFA (free fatty acids) level was determined.
As shown in Fig. 6A, the FFA level was markedly reduced by high fat
diet, a phenomenon that could be completely rescued by the sup-
plementation of high-dose BMSO. As the product of triglyceride
hydrolysis, serum FFA concentration is determined by lipid meta-
bolism and oxidation rate. Therefore, the increased serum FFA
could signal an enhanced lipid metabolism. Combined with the
invariable energy consumption, it could be deduced that changes of
energy expenditure might mediate BMSO's repairment for the
imbalanced energy homeostasis caused by obesity.
Leptin is a signaling molecule released by fat cells, and it could
aid in the maintenance of energy homeostasis [28]. The aberrant
leptin level was often accompanied by obesity, as also demon-
strated in this study (Fig. 6B). The increased circulating leptin level
could induce the leptin resistance, which directly led to the loss of
regulatory function of CNS, thereby detrimental for the mainte-
nance of energy balance. Given this context, the administration of
BMSO signiﬁcantly lowered the serum leptin level (Fig. 6B), and this
superior effect could be induced by both high and moderate doses.
Therefore, leptin was involved in the BMSO-led recovery and
played critical regulatoryroles. Besides, due to leptin's dynamic and
pluripotent properties, how BMSO affected the energy homeostasis
via the function of leptin remains to be investigated. And what's
more, as leptin is tightly associated with CNS's regulatory function
[29], whether this metabolism-controlling center was also involved
in BMSO's anti-obesity effect, needs a further validation.
4. Conclusions
In conclusion, BMSO was ﬁrst extracted using supercritical
methods, and the anti-obesity effect of the resultant CFA compound
was comprehensively investigated. The novel BME, rich in CLnA
and CLA, showed a potent effect represented by the alterations of
the murine adipocyte, plasma and liver. Subsequently, this beneﬁ-
cial effect was partially interpreted as the increased lipid meta-
bolism, and leptin also participated in the overall regulating
process. This is a detailed exploration of BME's anti-obesity effect,
facilitating the rational use of this herbal plant to address this
increasingly severe issue, obesity.
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